Date: 2012-04-17
Type of information: Development agreement
Compound: recombinant interferon product
Company: Angel Biotechnology (UK) TransGenRx (USA)
Therapeutic area:
Type agreement: development
Action mechanism:
Disease:
Details: The biopharmaceutical contract manufacturer Angel Biotechnology has agreed a contract with TransGenRx for the development and scale up of a recombinant interferon product. The purpose of the contract is to attain acceptable expression levels on which to establish a GMP manufacturing process, which would then be conducted by Angel.
Financial terms: This development work for TransGenRx will take place at Angel\'s GMP facility at Cramlington and will have a value in excess of £800,000 ($1.3 million).
Latest news: